Background: To evaluate the effectiveness and tolerability of add-on sitagliptin in elderly Taiwanese patients with Type 2 diabetes mellitus who have inadequate glycemic control to existing oral antidiabetic agents (OADs) combination regimens. Methods: Patients were randomized to receive the existing OAD combinations or add-on with sitagliptin (100 mg daily) for 24 weeks. We measured HbA1c, fasting plasma glucose, 2-hours postprandial plasma glucose, body mass index, and recorded the hypoglycemic episodes before and after 24 weeks of adding sitagliptin 100 mg once daily to existing maximal dose of OAD combination therapy for 24 weeks. Results: Compared with the change of 0.0% (95% confidence interval: À0.6% to 0.5%) from a baseline of 10.0% in the controlled arm, HbA1c change from a mean baseline of 9.5% was À1.14% AE 1.18 after add-on sitagliptin. Confirming significant differences (p < 0.0001), sitagliptin was generally well tolerated in all study patients. The between-groups difference in body mass index was not significant after 24 weeks of treatment. Conclusion: In elderly Taiwanese patients with Type 2 diabetes mellitus with inadequate glycemic control from OAD combination, the addition of sitagliptin provided significant HbA1c lowering the efficacy over 24 weeks.
Background
The management of elderly patients with Type 2 diabetes mel litus (T2DM) has become more complicated because of age-related physiological changes 1, 2 . In this population, the use of pharmaco logical agents also become more difficult as the pancreatic b-cell function declines over time together with the altered kidney and hepatic functions. Combination use of multiple antidiabetic drugs often are required to help these patients to reach the goal because of the progressive nature of the disease 3, 4 . There is limited data regarding the use of pharmacologic agents in older adults with T2DM. The use of recently available newer antidiabetic agents dipeptidyl peptidase-4 (DPP-4) inhibitors is attractive because of the desirable characteristics, including once-daily dosing and minimal risk of hypoglycemia when used as monotherapy 5, 6 . Sitagliptin is the only approved DPP-4 inhibitor in Taiwan. By inhibiting the DPP-4, sitagliptin enhances the incretin axis resulting in an increase in insulin synthesis and release and decrease glucagon secretion in a glucose-dependent manner. Sitagliptin is effective as mono therapy 7e9 , as initial combination therapy with metformin 10 , and as dual or triple combination with oral antihyperglycemic agents 11 . Safety and tolerability have been demonstrated in clinical trials up to 2 years, with a low risk of hypoglycemia during monotherapy or when used in combination with other antidiabetic agents not known to cause hypoglycemia 12 . Clinical data regarding sitagliptin use in elderly patients are limited 13, 14 . The present study examined the effectiveness and tolerability of add-on sitagliptin in elderly T2DM patients with inadequate control to existing oral antidiabetic agent (OAD) combination regimens.
Study methods and procedures

Study design and patients
This was a 24-week, randomized, open-labeled, parallel-group study. Eligible patients were male or female, older than 65 years, taking OAD combinations (sulfonylurea, metformin, and alphaglucosidase inhibitors) therapy but had inadequate response as determined by HbA1c level of 7% or higher. Patients were excluded if they had any significant diseases that were likely to affect the outcome and compliance of this study. Such diseases or conditions included heart failure, hepatic dysfunction, renal insufficiency with a creatinine level of 1.5 mg/dL or higher, and use of insulin pumps. Patients who had received any educational program for diabetes management from elsewhere other than ours were also excluded. Written informed consent was obtained from each participant.
Patients were randomized to continue their existing OAD combinations or add-on with sitagliptin (100 mg daily) for 24 weeks. We measured HbA1c, fasting plasma glucose (FPG), 2-hours postprandial plasma glucose (PPG), body mass index (BMI), and recorded the hypoglycemic episodes and other adverse event (AE) at baseline, Week 12, and Week 24 during the study period. Participants in the both groups visited our medical doctors at least three times during the 24-weeks study period. All study patients were provided with disease education and treatment information, dosing regimen, lifestyle modification, and so on by the trained specialists in our outpatient department during each follow up visit. A more individualized and detailed information about diet recommendation and lifestyle modification were also given by dietician on as needed basis.
Evaluations
The primary endpoint was the percent changes of HbA1c between two groups after 24 weeks of treatment. Other efficacy endpoints included FPG and 2-hour PPG. Body weight was measured at baseline, Week 12, and Week 24. Safety and tolera bility were assessed by collecting the AEs.
Statistical methods
Student t test was used for within-group comparison, analysis of covariance was used to adjust baseline HbA1c values for betweengroup comparison, a p value less than 0.05 was considered to be significant.
Results
One hundred ten elderly patients with T2DM were screened, 13 patients were not randomized because of failure to meet gly cemic inclusion criteria at baseline. All randomized patients who received at least one dose of study drug were included in the data analysis. The two treatment groups were generally well balanced with respect to baseline demographics and disease characteristics (Table 1) . Mean age (standard deviation) was 73.5 (5.9) in sita gliptin group and 72.5 (5.2) in the control group; mean diabetes duration was 13.7 years in both groups. All patients were receiving OAD combinations (sulfonylurea, metformin, and alphaglucosidase inhibitors) therapy, with HbA1c level of 7% or higher (mean HbA1c levels: 9.5% in sitagliptin group and 10.0% in control group).
The addition of sitagliptin 100 mg to existing OAD combination regimens significantly reduced HbA1c (À1.3%), FPG (À38.3 mg/dL), and PPG (À60.0 mg/dL) (all p < 0.0001) at 24 weeks compared with baseline value but no significant reductions in these parameters were found in the control group (Table 2 and Fig. 1 ). The least square mean change of HbA1c from baseline between groups at Week 24 was also significantly different (p < 0.0001). At Week 24, an additional 26.5% patients in the sitagliptin group achieved the treatment goal of HbA1c level of 7% or less. Sitagliptin was generally well tolerated in all study patients. The between-groups difference in BMI was not significant after 24 weeks of treatment (Table 3) , which indicated no increase in body weight after add-on sitagliptin. Only one hypoglycemic episode was reported in the sitagliptin group. No significant differences were observed between groups regarding the overall incidences of AEs, drug-related AEs, serious AEs, serious drug-related AEs, and study discontinuations because of AEs (Table 4 ).
Discussion
T2DM can be complicated and difficult to treat in elderly patients. Glycemic goals in elderly patients and interventions to achieve such goals must take into account the clinical status of individual patients to avoid unexpected comorbidities. Balance between achieving glycemic goals and avoiding hypoglycemia can be a challenge as advanced age itself can contribute to the risk of hypoglycemia because hypoglycemia can have a profound impact on health outcomes and quality of life in elderly patients. Unfor tunately, recognition of hypoglycemia may be diminished in the elderly, the warning symptoms of hypoglycemia, such as shaky, weak, sweating, or hungry complaints may be absent or diminished with autonomic neuropathy. Existing antidiabetic regimens thus pose increased risk for hypoglycemia in the elderly patients. On the other hand, because of the progressive nature of T2DM, there are many patients who do not achieve glycemic control only by OAD, insulin may provide additional glycemic benefits, but in practice, patients and physicians are often resistant to this approach because of various factors, including an increased risk of hypoglycemia or weight gain and practical barriers to insulin therapy adjustments 15 .
The new incretin-based therapies offer advantages over standard medications by improving glucose-dependent insulin secretion. Barnett 16 reported that the oral gliptins can be combined with other OADs and also with insulin, whereas the most important combination is with metformin, and one of its most important benefits is its lack of weight gain 17 . All our study patients had received combination regimens of metformin, alpha-glucosidase inhibitors, and sulfonylurea, which are the most commonly used drug classes prescribed in T2DM; but often being associated with weight gain and hypoglycemic episode, especially in elderly patients, the fears of AE often lead to noncompliance in medication and lifestyle modification, which, in turn, led to poor glycemic control and failure to achieve treatment goal.
In the present study, clinical AEs of hypoglycemia, selected gastrointestinal events (diarrhea), upper respiratory tract infection, and urinary tract infection, as well as BMI changes were prespecified as AEs of interest and were observed closely throughout the study period. Sitagliptin was shown to be well tolerated, the incidence of hypoglycemia was similarly low (0%e2%) between both treatment groups, with no episode of hypoglycemia exhibit ing marked severity, although Williams-Herman et al 12 reported
that sitagliptin was generally well tolerated with an overall inci dence of AEs comparable with placebo, a low risk of hypoglycemia or gastrointestinal AEs, and a neutral effect on body weight. Charbonnel B et al 18 and Gagliardino et al 19 all stated that because metformin reduces hepatic glucose production and increases glucagon-like peptide 1 release, combined therapy of metformin and sitagliptin provides complementary and additive effects through regulating the glucose-dependent insulin secretion and suppression of glucagon concentrations, with no significant increase in AEs of hypoglycemia. However, when exogenous insulin that is not regulated by ambient glucose or incretin is added, the incidence of hypoglycemia may not be unexpected with the addition of sitagliptin to the treatment regimens. Different rates of hypoglycemia have been reported with DPP-4 inhibitors when added to ongoing OAD or insulin therapy. Pratley et al 6 had also reported the experience of alogliptin used in elderly people showing improvements in HbA1c similar to those seen in younger patients, and no increase in the risk of hypoglycemia, weight gain, or other AEs. The differences across studies may be related to study population, including different age and race, years of diabetes duration, entry criteria, baseline HbA1c/FPG, dose and regimen, responses to treatment, and importantly, the different definitions of hypoglycemia. In our study, sitagliptin also demonstrated a neutral effect on body weight after 24 weeks of treatment. The improvements of glycemic control both in the fasting and postprandial states were not accompanied by an increase in body weight relative to the control group. We believe that the glucose-dependent mechanism of DPP4 inhibitor may contribute to increase medication compli ance and diet control and break the vicious cycle mentioned above after taking the conventional antidiabetic medication.
There are several limitations to the present study. First, as an open-labeled study, a placebo effect may exist that can be neither be discounted nor estimated. However, the bias are less likely to occur in the efficacy endpoints of this study, which were deter mined through laboratory tests but may more likely occur in the safety evaluation by knowing the changes in treatment regimen. Second, the number of subjects was too small to be stratified for subgroup analysis according to patients' baseline HbA1c levels; therefore, we could not analyze the association between glycemic variables and efficacy/impact of sitagliptin treatment. Third, the duration of our study was short, further clinical studies are necessary to evaluate the long-term effects of sitagliptin as add-on therapy for elderly patients with T2DM. Future clinical studies should evaluate whether this add-on therapy has the potential to delay progression or prevent elderly T2DM.
In conclusion, our study in Taiwanese elderly patients with T2DM with inadequate glycemic control from OAD combination, the addition of sitagliptin provided significant HbA1c lowering efficacy over 24 weeks.
